ahlam1399
07-22-2015, 11:47 AM
AstraZeneca drug selumetinib fails in uveal mela**ma trial
LONDON, July 22 (Reuters) - AstraZeneca's much anticipated cancer drug pipeline suffered a blow on Wednesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for uveal mela**ma.
http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/1/rc.img (http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/1/rc.htm)
http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/2/rc.img (http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/2/rc.htm)
http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/3/rc.img (http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/3/rc.htm)
http://da.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/a2.img (http://da.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/a2.htm)
http://adchoice.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/ach.img (http://adchoice.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/ach.htm)http://pi.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/a2t.imghttp://pi2.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4853919a/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=Y6XPDeIbrhM:Fu_j4U4rgJE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Y6XPDeIbrhM:Fu_j4U4rgJE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=Y6XPDeIbrhM:Fu_j4U4rgJE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Y6XPDeIbrhM:Fu_j4U4rgJE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=Y6XPDeIbrhM:Fu_j4U4rgJE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/Y6XPDeIbrhM
LONDON, July 22 (Reuters) - AstraZeneca's much anticipated cancer drug pipeline suffered a blow on Wednesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for uveal mela**ma.
http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/1/rc.img (http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/1/rc.htm)
http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/2/rc.img (http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/2/rc.htm)
http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/3/rc.img (http://rc.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/rc/3/rc.htm)
http://da.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/a2.img (http://da.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/a2.htm)
http://adchoice.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/ach.img (http://adchoice.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/ach.htm)http://pi.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/a2t.imghttp://pi2.feedsportal.com/r/234565885988/u/49/f/654213/c/35217/s/4853919a/sc/21/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4853919a/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=Y6XPDeIbrhM:Fu_j4U4rgJE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Y6XPDeIbrhM:Fu_j4U4rgJE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=Y6XPDeIbrhM:Fu_j4U4rgJE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=Y6XPDeIbrhM:Fu_j4U4rgJE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=Y6XPDeIbrhM:Fu_j4U4rgJE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/Y6XPDeIbrhM